UNSPSC 51272701: Methionine

This classification denotes a dietary amino acid with the molecular formula C5H11NO2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AE28F7PNPL, chemically known as methionine which bears US NIH Compound Identifier 876. European Medicines Agency schedules methionine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21984. The term METHIONINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3).

UNSPSC 51272701 Methionine is a Commodity code, but the recent state and local opportunities tagged under it do not involve methionine procurement. Instead, the three most recent opportunities cover naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products — none of which align with the code's nominal scope of amino acid commodity supply. The mismatch suggests that methionine as a standalone chemical input sees little direct state and local procurement activity, or that issuing bodies are consistently miscoding pharmaceutical and medical-supply acquisitions under this Commodity designation.

The three opportunities reveal purchasing primarily by state health and human services agencies and county health departments rather than traditional commodity buyers. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023 (noting a date discrepancy in the source). The Texas Health and Human Services Commission released RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for direct-to-manufacturer prescription programs serving state employees and self-insured health plans. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities in Minnesota and Oregon, with responses due March 26, 2026. Geographic activity appears concentrated in Florida, Texas, and the Upper Midwest. The code shows no clear methionine-specific state and local demand signal in current procurement.